What this study is
The purpose of this study is to collect blood samples to detect potential markers of pancreatic cancer in the blood and link these findings to medical and health information. Information from this study may help to provide insight into the detection of pancreas cancer in the blood before it can be found by other methods or provide a method of monitoring the status of pancreatic cancer throughout a treatment course. Another purpose of this study is to collect blood to create a biobank.
Study details
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Conditions
- Pancreatic Diseases
- Enrolling
- 100 people
- Starts
- 2015-09-10
- Est. completion
- 2035-01-01
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- The subject must be a patient at the Hospital of the University of Pennsylvania; The subject must be under evaluation and/or treatment for a pancreatic disease; The subject must be under evaluation and/or treatment for a non-pancreatic disease. For example, patients undergoing routine colonoscopy within the clinical practice will be asked to consent to provide control samples.
- The subject must be able to provide informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf
- The subject must be 18 years of age or older
You can't join if
- The subject or acceptable surrogate does not provide informed consent
- Subject is a prisoner
- Subject is under 18 years of age
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openAbramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Study team
Sponsor
Abramson Cancer Center at Penn Medicine
Study ID UPCC 02215
Principal investigator
Peter O'Dwyer, MD
Abramson Cancer Center at Penn Medicine
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.